Usrc - Villa Park Home Therapies is a medicare approved dialysis facility center in Villa Park, Illinois and it has 0 dialysis stations. It is located in Du Page county at 202 East North Avenue, Villa Park, IL, 60181. You can reach out to the office of Usrc - Villa Park Home Therapies at (630) 415-3458. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. Usrc - Villa Park Home Therapies has the following ownership type - Profit. It was first certified by medicare in October, 2015. The medicare id for this facility is 142787 and it accepts patients under medicare ESRD program.
| Name | Usrc - Villa Park Home Therapies |
|---|---|
| Location | 202 East North Avenue, Villa Park, Illinois |
| No. of Dialysis Stations | 0 |
| Medicare ID | 142787 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 202 East North Avenue, Villa Park, Illinois, 60181 | |
| (630) 415-3458 | |
| Not Available |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago
| NPI Number | 1649675950 |
| Organization Name | U S Renal Care Villa Park Home Dialysis Program |
| Doing Business As | Usrc Vp Home, Llc |
| Address | 202 E North Ave Villa Park, Illinois, 60181 |
| Phone Number | (630) 415-3458 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 5 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 13 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 89 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 60 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Usrc - Villa Park Home Therapies with elevated calcium levels.
| Patients with hypercalcemia | 13 |
| Hypercalcemia patient months | 89 |
| Patients with Serumphosphor | 14 |
| Patients with Serumphosphor less than 3.5 mg/dL | 4 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 36 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 29 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 4 |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.
ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.
New targeted pills can have dramatic effects on cancer, not only driving the disease into remission but also freeing patients from hours of uncomfortable and boring chemotherapy treatments. Up to 10 percent of patients, however, are not filling their prescriptions for the pills-and cost appears to be a factor, according to a new report.
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Both studies are now accepting new participants.
› Verified 2 days ago